
    
      MIP-IB12B, the pivotal phase 2 study evaluating efficacy and safety of AZEDRA in patients
      with malignant relapsed/refractory PPGL, has completed its anticipated enrollment. The
      purpose of this sub-study, MIP-IB12B-EAP, is to provide expanded access to AZEDRA for newly
      enrolled subjects with iobenguane-avid metastatic and/or recurrent PPGL and to collect
      additional safety data.
    
  